Perrigo Company plc filings document a consumer health issuer organized under Irish law, with disclosures covering operating results, non-GAAP measures, segment reporting, capital structure, governance, and material corporate events. Recent 8-K filings report quarterly earnings from continuing operations, the company's transition to product-category segments, and the completed sale of its Dermacosmetics branded business.
The filing record also covers Perrigo's ordinary shares, senior notes, revolving credit facility, and term loan arrangements, including amendments to credit agreements. Proxy and annual meeting materials document board matters, shareholder voting results, executive compensation, and the shareholder-approved 2026 Long-Term Incentive Plan.
Perrigo Company plc (PRGO) Form 4/A corrects an earlier filing to show that on 08/18/2025 the reporting person, Geoffrey M. Parker, had 4,375 ordinary shares acquired at a price of $22.9708, and those shares were acquired indirectly by the Geoffrey M. Parker Roth IRA rather than directly. After this transaction the Roth IRA held 9,875 shares. The filing also lists other holdings: 28,912 ordinary shares disposed (as reported) and 25,879 ordinary shares held indirectly via a revocable trust in which Geoffrey and Jill Parker are trustees. The amendment states the only change from the original Form 4 is correcting the manner of acquisition to reflect the IRA ownership. The form is signed by an attorney-in-fact for Mr. Parker on 08/19/2025.
Geoffrey M. Parker, a director of Perrigo Company plc (PRGO), purchased 4,375 ordinary shares on 08/18/2025 at $22.9708 per share. Following the purchase, Mr. Parker is reported to beneficially own 33,287 shares directly and holds additional indirect holdings of 25,879 shares through a revocable trust and 5,500 shares in a Roth IRA, as disclosed on Form 4. The filing was signed by an attorney-in-fact on 08/19/2025 and includes explanatory notes identifying the trust and the Roth IRA as the vehicles for indirect ownership.
Perrigo Company plc insider filing shows EVP & Chief Financial Officer Eduardo Bezerra purchased 3,000 ordinary shares on 08/18/2025 at a reported price of $22.7356 per share, increasing his beneficial holdings to 48,949 shares. The Form 4 was signed by an attorney-in-fact on 08/19/2025. The filing contains no additional transactions or derivative activity.
State Street Corporation reported beneficial ownership of 7,340,323 shares of Perrigo Co plc common stock, representing 5.3% of the class. The filing is a Schedule 13G and shows shared voting power of 6,531,899 and shared dispositive power of 7,340,323, with no sole voting or dispositive power reported. The submission names multiple State Street advisory subsidiaries as related entities and includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.
Form 4 summary: Reporting person Patrick Lockwood-Taylor (Director; CEO) filed a Form 4 for PERRIGO Co plc (PRGO) reporting purchases on 08/08/2025.
Transactions: Ordinary shares acquired: 4,060 at $22.3682 (beneficial ownership after: 85,412); 346 at $22.38 (85,758); 54 at $22.37 (85,812). The form is signed by attorney-in-fact Diana Witt on 08/08/2025.
Perrigo Company plc — Quarterly highlights (Q2 ended June 28, 2025)
Net sales of $1,056.3M for the quarter and $2,100.2M for six months, down vs. prior year. Gross profit for the quarter was $362.9M. Operating income improved to $45.4M (vs. a loss of $26.5M a year ago); continuing operations reported a small loss of $0.5M for the quarter. Discontinued operations produced a loss of $7.9M, and diluted EPS was a loss of $0.06 for the quarter and $0.10 for six months.
Balance sheet and cash: cash and equivalents $454.2M (down $104.6M YTD); inventories increased to $1,215.5M. Total assets $10,094.1M; total liabilities $5,621.8M. Total borrowings outstanding $3,651.9M. Notable items: sale of Richard Bittner Business for $14.4M (pre-tax loss $1.6M); Prevacid impairment $1.5M; litigation accrual for price-fixing $30.0M with a 50% recovery receivable under indemnity (Altaris cap $50.0M). Foreign currency translation increased comprehensive income, producing comprehensive income of $137.0M for the quarter.
Perrigo Company plc (NYSE: PRGO) has signed a definitive Master Sale and Purchase Agreement dated 13 July 2025 to divest its Dermacosmetics branded business in Northern Europe, the Netherlands and Poland to Kairos Bidco AB, an investment vehicle managed by an affiliate of KKR. The transaction covers 100 % of the shares of Aco Hud Nordic AB and ancillary production, packaging and distribution assets.
Transaction economics: Kairos will pay €300 million in cash at closing, subject to customary working-capital, inventory, debt and cash adjustments. Perrigo is also eligible for up to €27 million of contingent consideration tied to performance milestones over a three-year period. Post-closing, Perrigo will provide transition services for a fee.
Timing & conditions: Closing is targeted for Q1 2026 and is contingent on (i) antitrust and other regulatory approvals, (ii) completion of agreed pre-closing restructurings, (iii) works-council consultations in certain jurisdictions and (iv) consummation of KKR’s separate acquisition of Karo Healthcare. Either party may terminate if the deal is not completed within 18 months.
Key covenants: Until closing, Perrigo must operate the Dermacosmetics business in the ordinary course, seek Kairos’s consent for certain actions, enter into non-compete and non-solicitation agreements, and continue marketing investment. Standard reps, warranties and indemnities apply; certain confidential schedules are omitted.
Strategic context: The sale further rationalises Perrigo’s portfolio after earlier divestitures (Rx, HRA Rare Diseases, Hospital & Specialty) and adds liquidity that can be redeployed toward core consumer-self-care operations or debt reduction. Management disclosed the deal via Form 8-K (Item 1.01) and a press release (Exhibit 99.1).
Perrigo Company plc (PRGO) – Form 4 insider filing: Executive Vice President & President of CSCI, Roberto Khoury, reported two transactions dated 8 July 2025.
- Disposition: Khoury disposed of 5,205 ordinary shares (Table I, coded “D”). No price information was supplied in the excerpt.
- Acquisition (equity award): He received 2,211 Restricted Stock Units (RSUs) (Table II, coded “A”). Each RSU converts to one ordinary share and vests in three equal annual instalments beginning 8 July 2026.
Following the transactions, Khoury directly owns the newly granted 2,211 RSUs; the filing does not disclose his remaining ownership of ordinary shares beyond the figures above. The activity is routine executive equity compensation combined with a modest share sale, providing limited insight into fundamental performance but useful for monitoring insider sentiment and potential dilution.